Literature DB >> 29414500

Priapism as the initial sign in hematologic disease: Case report and literature review.

Luis Cuitláhuac Becerra-Pedraza1, Luis Enrique Jiménez-Martínez2, Iran Peña-Morfin3, Rogelio Nava-Esquivel4, Juan Alfredo Villegas-Martínez2.   

Abstract

INTRODUCTION: Priapism is an uncommon sign and sometimes considered a diagnosis challenge into systemic disease; this is defined as ≥4 h continuous penile erection, without sexual stimulation. We state that this work has been reported in line with the SCARE criteria PRESENTATION OF CASE: A Mexican 52-year-old man was brought to the emergency room with priapism of six days of evolution. His medical history reported fatigue and waxy pallor had begun a month ago, the rest of interrogation was unremarked. Hyperleukocitosis (>250,000 cells/ml) was documented on his preoperative evaluation, the initial step was hematology consultation due to malignance suspicion, followed by corpora cavernosa drainage-irrigation and surgery penis shunts. After of procedure, we realized bone marrow aspiration, kariotype and cytogenetic analysis, histopathological and moleculars assay reported myeloid hyperplasia compatible with acute phase CML and Philadelphia translocation t(9:22) (q34;q11.2) with P210 BCR-ABL1 fusion transcriber, patient was discharged with dasatinib for maintenance phase. Actually, he has a satisfactory evolution without relapses. DISCUSSION: The majority of reported cases shows the individual importance of hematological diseases in priapism as it is shown in the analysis of the literature of 10 years (2006-2016) that we made. It is imperative to consider the type of priapism, and the genetic and demographic patient aspects due to the early and correct approach improves the short and long term outcome of the hematological patients.
CONCLUSION: Priapism is an uncommon sign of systemic disease. In the presence of warning signs, malignancy should be considered until proven otherwise.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Case report; Chronic myeloid leukemia; Leukemic priapism; Malignant priapism; Priapism

Year:  2018        PMID: 29414500      PMCID: PMC5907689          DOI: 10.1016/j.ijscr.2017.12.038

Source DB:  PubMed          Journal:  Int J Surg Case Rep        ISSN: 2210-2612


Introduction

Priapism is a condition characterized by ≥4 h continues penile erection, without sexual stimulation. There are two types of priapism: ischemic and nonischemic [1]. The most common causes of Ischemic Priapism (IP) include idiopathic (65%), hematological disorders [HD] (20%) and other causes 15% [2]. By definition, Malign Priapism (MP) appears in the frame of a solid or liquid neoplasm such as: bladder (30.6%), prostate (29.6%), recto-sigmoid (14%), kidney (6.6%) and leukemia (0.7%) [3] of this the fifty percent attributed to Chronic Myeloid Leukemia (CML). CML is an abnormal mature B cells clonal proliferation which appears with an abnormal function, and is characterized by the presence of the translocation 9:22 (BCR-ABL 1 positive [PC]). CML distribution has two periods, the first one is in the elementary age (∼7 yrs) and the second varies widely in a range from 20 to 50 years old (∼35 yrs) [4]. CML clinical presentation is lymphadenopathy (80%), asthenia and fatigue (60%), spleen or liver enlargement (50%), weight loss (15–20%), and bleeding (10%), hyperleukocitosis about 80%, central nervous system affection (15%) kidney (5%) and MP (≤3%). MP diagnosis is clinic, this is based in anamnesis and physical exploration, followed by Corpora Cavernosa Blood Gas Analysis (CCBGA) and Doppler Color Ultrasound (DCU) to identify local ischemia. MP cases are a medical challenge, where the underlying disease has to be elucidated and treated. Finally, MP treatment is based on anticoagulants, fibrinolysis, puncture-aspiration and vasoactive agents injection. At the end, surgery is reserved only if conservative therapy is unsatisfactory and in special conditions which is necessary a specific treatment of the underlying disease [[5], [6], [7], [8], [9]]. We state that this work has been reported in line with the SCARE criteria [34].

Case report

A Mexican 52-year-old man without cancer history began with weight loss, generalized fatigue and pallor one month ago. He was brought to the emergency room with a painful six-day evolution priapism, gradually increased in severity and impaired ambulation. He denied swelling and fever. During physical examination ischemic priapism was observed. He denied a trauma history, drug abuse, arousal stimulation or previous similar episodes. Preoperative analysis was taken, showed: Hemoglobin 10 gr/dl (14–16 gr/dl), white blood cells 282,000/mm3 (7000–10,000/mm3), platelets 368,000/mm3 (150,000–400,000 mm3), lactic dehydrogenase 1503 UI/L (125–220 IU/L) the studies remaining performed were normal, chest x-ray and electrocardiography without findings. The initial step was hematology consultation due to malignance suspicions. Informant consent was gotten before treatment started, treatment was started administering hyperhydratation and allopurinol. Followed by corpora cavernosa drainage-irrigation and surgery penis shunts. After of procedure, we realized bone marrow aspiration, kariotype and cytogenetic analysis, histopathological and moleculars assay report noted myeloid hyperplasia compatible with acute phase CML and Philadelphia translocation t(9:22) (q34;q11.2) with P210 BCR-ABL1 fusion transcriber (Fig. 1). The patient was discharged with dasatinib 100 mg/day by maintenance phase. and the subsequently medicals appointments was established. Currently, the leukemia is in satisfactory evolution without relapses.
Fig. 1

A) Post-operative surgical image shows the system corpora cavernosa drainage-irrigation. B) Kariotype image display Philadelphia translocation t(9:22. [q34; q11.2]) (Full arrow).

A) Post-operative surgical image shows the system corpora cavernosa drainage-irrigation. B) Kariotype image display Philadelphia translocation t(9:22. [q34; q11.2]) (Full arrow).

Literature review

Etiopathogenic

About 50% of idiopathic priapism correspond to IP or Low Flow Priapism (LFP; also called veno-occlusive). There is a strong association with HD, systemic vasoactive drugs, malignancy and neurological disorders. On the other hand, non-IP or High Flow Priapism (HFP) often occurs due to a pelvic trauma and after intracavernosal injections [10,11] (see Table 1) [12].
Table 1

Principal causes of Ischemic Priapism.

Neurological DisordersIdiopathic DrugsIdiopathic Drugs (Continuation)Idiopathic Drugs (Continuation)Metastatic
SyphilisAnticoagulantsHypnoticsPapaverinePenis
StrokeHeparinClozapineProstoglandin E1Recto-sigmoid
Brain tumorsWarfarinDiazepamSildenafilProstate
EpilepsyAntihypetensivesBlockersTestosteroneKidney
IntoxicationDihydralazineTamsulosinHematological DisordersMetabolic Disorders
Brain or spinal cord injuriesLabetalolDoxazosinSickle cell anemiaAmyloidosis
Lumbar disk herniation or stenosisNifedipinePrazosinLeukaemiaFabry’s disease
Cauda equine syndromePhenoxybenzamineRecreational drugsMultiple myelomaDiabetes
Regional or general anesthesiaPrazosinCocaineThalassaemiaNephrotic syndrome
AntidepressantsEtanolParoxysmal nocturnal haemoglobinuriaRenal failure
PhenelzineMarijuanaThrombocythaemiaHaemodialysis
TrazadoneDrugs for intracavernous injectionHenoch-Schonlein purpuraIdiopathic
Principal causes of Ischemic Priapism.

Pathophysiology

The physiopathology can be separated in 2 ways, as “non-ischemic” triggered by a trauma, which causes an irregular cavernous arterial flow and the formation of fistulas, and the most common is “ischemic” which is most commonly idiopathic-related but is also due to hematological etiologies [12]. Inside hematological causes are the hemoglobinopathies which are ahead and less common hyper-viscosity states such as leukemia, occurring during prolonged nocturnal erections, decreasing venous flow return and the mechanism of normal detumescence, is a rare syndrome characterized by multiple and recurrent episodes of ischemic priapism. In normal erection the corpus cavernosum flow facilitates the synthesis of nitric oxide (NO) and prostaglandins (PGI2), its function is to regulate the interaction between stagnant blood and the trabecular wall [13]. In ischemic priapism, hypoxia and ischemia alter the synthesis of NO and PGI2, causing homeostatic imbalance, facilitating platelet aggregation and increasing adhesion of white blood cells, leading to thrombus formation and tissue damage, venous thrombosis with persistent vascular block that leads to pain at 4 h, platelets adhere to the basement membrane of sinusoidal spaces and proliferation of fibroblasts, the glycopenia of HD also alter the smooth muscle [8,13]. Ischemia of 32 h duration, causes endothelial and trabecular destruction, with subsequent irreversible fibrosis and calcification, leading to erectile dysfunction [8]. The molecular mechanisms that may lead to HD priapism are: adenosine deaminase deficiency leading to excessive levels of adenosine causing priapism and opiorphin to the via ornithine decarboxylase [8,10]. Finally hyperviscosity by excess leukemic cells are added to the corpora cavernosa and dorsal veins of the penis, decreased flow and stagnation of the blood, resulting in LFP. Another contributing factor in the venous congestion of the corpora cavernosa is the mechanical pressure on the abdominal veins by the splenomegaly [8].

Diagnosis

Medical history diagnosis and directed interrogation are the initial step by determine the priapism etiology. The initial exploration has to look early signs of ischemia (pain, paleness, paresthesias, color changes and function loss) The presence of extra-urological signs and symptoms (splenomegaly, adenomegaly and weight loss) must suggest malignancy [8,10,12]. Some signs (e.g. Piesis Sign) can differentiate flow features, however they are rare findings, and commonly viewed in pediatric patients with HFP [12]. CCBGA must be performed to differentiate IP to non-IP. The normal arterial blood analysis has similar values than HFP (pO2 >90 mmHg, pCO2 < 40 mmHg, pH 7.4) furthermore, LFP (pO2 < 30 mmHg, CO2 > 60 mmHg, pH > 7.25) show abnormal levels. The use of magnetic resonance is limited, it can predict smooth muscle viability and erectile function restoration post-event. Finally, elected pudenda arteriogram can be diagnostic and therapeutic, it should be reserved for the management of arterial priapism when embolization is required [14].

Treatment

There are several ways of treatment which begin into conservative measures to complex surgical techniques. Control pain with penile anesthesia or systemic analgesia is considerate a key measure to decrease the adrenergic response, and decreasing patient’s distress. Nevertheless, anesthesia sometimes does not relieve ischemic pain, so is necessary perform hard interventions doing use of local nerve block or even sedation drugs [14]. Mild invasive measures can helps patients while surgery is available, aspiration-irrigation can be an initial invasive measure; followed by intracorporal sympathomimetics drugs (phenylephrine, etilephrine, epinephrine and norepinephrine) alone or mixed with aspiration-irrigation, both are considered an effective measures [10]. Surgery is reserved only if conservative therapy was unsatisfactory. Several surgical options may be considered depending of patient’s particular setting and evolution time [14]. Surgery penis shunts (distal-shunt) has a higher performance, this can be done easily and has minimal complications compared with the proximal-shunts. On the other hand, surgical prosthesis implantation are the last rung and should be considered in patients with refractory or recurrent priapism associated with erectile dysfunction [10,14]. The main step is establishing specific treatment of the underlying disease, as well as early hematological consultation [10,15] (Table 3).
Table 3

Therapeutic steps in malignant priapism.

*Oral sympathomimetics, such as etilferine, phenylephrine, metaraminol and terbutaline, are superior to placebo if administered within a short timeframe (<4 h) after onset of priapism. This’s complement treatment while other measures are being.

**Tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib and nilotinib, are being commenced immediately the diagnosis of CML is confirmed.

***Leukapheresis may be used as a complement to systemic chemotherapy.

WBC: With Blood Cell.

Discussion

Priapism is an uncommon sign into systemic disease. The iatrogenic cause is secondary to overuse of erectile dysfunction medications. In the United States IP is the most common presentation of priapism, with an incidence of up to 5.34 per 100,000 men per year. Hematological diseases in children can develop priapism. In the present case, our patient was diagnosed with CML and secondary hyperleukostasis. This underlay mechanism lead to corpora cavernosa venous congestion by neoplastic cells and viscosity blood increasing, although HD are uncommon causes of priapism, we must think in all of them as a possible etiology. There are several case reports that show the individual importance of CML and priapism, we made a literature analysis (ScienceDirect, Medline and Pubmed) from 2006 to 2016 using the keywords: “priapism; leukemia; chronic myeloid leukemia; priapismo; leucemia mieloide crónica” looking for a 9;22 translocation and priapism type flow (Table 2).
Table 2

Ten years literature review previous cases with Priapism CML from 2006 to 2016.

Author(s)/YearPriapism-CML casesAge onsetPhiladelphia chromosomeType of priapismCountry
Pal et al. 2016 [15]1NIANIALFIndia
Nerli et al. 2016 [16]119 years old9:22 translocationLFIndia
Alao et al. 2016 [17]130 years old9:22 translocationLFNigeria
Almaeena et al. 2016 [18]136 years oldNIALFSaudi Arabia
Ergenc et al. 2015 [19]118 years old9:22 translocationLFTurkey
Shaeer et al. 2015 [20]121 years old9:22 translocationLFEgypt
Villegas et al. 2014 [21]224 and 29 years oldBoth 9:22 translocationLFSpain; Spain
Farhan et al. 2014 [22]138 years old9:22 translocationLFSaudi Arabia
Magaña et al. 2014 [23]132 years old9:22 translocationLFMexico
Hazra et al. 2013 [24]114 years oldNIALFIndia
Veljković et al. 2012 [25]116 years old9:22 translocationLFSerbia
Paladino et al. 2011 [26]116 years oldNIALFArgentina
Tazi. 2009 [27]130 years oldNon Karyotype AbnormalityLFMorocco
Jamel et al. 2009 [28]221 and 55 years oldBoth 9:22 translocationLFPakistan
Gupta et al. 2009 [29]112 years old9:22 translocationLFIndia
Htun et al. 2008 [30]121 years old9:22 translocationLFChina
Ajape et al. 2008 [31]230 and 41 years oldBoth 9:22 translocationLFNigeria; Nigeria
Gupta et al. 2008 [32]155 years oldNIALFIndia
Yoshida et al. 2007 [33]129 years oldNIALFJapan

CML: Chronic Myeloid Leukemia; NIA: No Information Available; LF: Low Flow.

Ten years literature review previous cases with Priapism CML from 2006 to 2016. CML: Chronic Myeloid Leukemia; NIA: No Information Available; LF: Low Flow. Therapeutic steps in malignant priapism. *Oral sympathomimetics, such as etilferine, phenylephrine, metaraminol and terbutaline, are superior to placebo if administered within a short timeframe (<4 h) after onset of priapism. This’s complement treatment while other measures are being. **Tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib and nilotinib, are being commenced immediately the diagnosis of CML is confirmed. ***Leukapheresis may be used as a complement to systemic chemotherapy. WBC: With Blood Cell. Malignancy red flags (weight loss, generalized fatigue and pallor) must be considered to underlying disease diagnosis. In our case, preoperative evaluation detected lymphocytic line affectation, so our initial suspicion was lymphoproliferative disorder. In regard to acute phase diagnostic, it should be oriented to detect ischemia through CCBGA and DCU with the purpose of make an early intervention (Table 3). Finally, the treatment should be multidisciplinary with medical oncologists, surgeons, urologists, radiologists, nursing and psychology. The early and correct diagnosis approximation improves at short and long term the outcome of the hematological patients. The acute phase treatment is lead to avoid local and systemic complications, which the patient stabilization and early consultation of internal medicine or hematology plays a predominant role. During chronic phase follow-up, continuous check-up and illness remission are the treatment of the underlying disease which improve the functional prognosis and consequently the survival. In conclusion, the present article exemplifies the importance of priapism in adult patients with hematological disease, with prompt diagnosis and standardized treatment, patients may have a good prognosis for life and function.

Patient perspective

– “Currently, I’m satisfied with my treatment, I hope to continue improving as I have been doing it so far.”

Conflicts of interest

None.

Funding

None.

Ethical approval

Ethical approval has been exempted by the institution, since it is not considered a risky investigation for the patient or for the researchers.

Consent

The informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editorial-in Chief of this journal on request.

Authors contribution

All authors contributed to this work, commented on the manuscript at all stages and finally approved the final version to be published. Becerra-Pedraza Luis Cuitláhuac: conceived and supervised study design, data collections, data analysis, writing. Jiménez-Martínez Luis Enrique: study design, data collections, data analysis, writing. Peña-Morfin Iran: study design, data collections, data analysis, writing. Nava-Esquivel Rogelio: study design, data collections, data analysis, writing. Villegas-Martínez Juan Alfredo: performing the surgery and surgical image collections.

Guarantor

Luis Cuitlahuac Becerra Pedraza.
  21 in total

Review 1.  Priapism as a result of chronic myeloid leukemia: case report, pathology, and review of the literature.

Authors:  Osama Kamal Zaki Mahmoud Shaeer; Kamal Zaki Mahmoud Shaeer; Islam Fathy Soliman AbdelRahman; Mostafa Shawky El-Haddad; Osama Mohamed Selim
Journal:  J Sex Med       Date:  2015-01-29       Impact factor: 3.802

Review 2.  Acute management of priapism in men.

Authors:  Yeng K Tay; Daniel Spernat; Kathryn Rzetelski-West; Sree Appu; Chris Love
Journal:  BJU Int       Date:  2012-04       Impact factor: 5.588

Review 3.  Priapism in hematological and coagulative disorders: an update.

Authors:  Belinda F Morrison; Arthur L Burnett
Journal:  Nat Rev Urol       Date:  2011-03-15       Impact factor: 14.432

4.  Leukapheresis in management hyperleucocytosis induced complications in two pediatric patients with chronic myelogenous leukemia.

Authors:  Dobrila Veljković; Milos Kuzmanović; Dragan Mićić; Olivera Šerbić-Nonković
Journal:  Transfus Apher Sci       Date:  2012-04-03       Impact factor: 1.764

5.  Chronic myeloid leukemia presented with priapism: Effective management with prompt leukapheresis.

Authors:  H Ergenc; C Varım; C Karacaer; D Çekdemir
Journal:  Niger J Clin Pract       Date:  2015 Nov-Dec       Impact factor: 0.968

6.  Successful use of terbutaline in persistent priapism in a 12-year-old boy with chronic myeloid leukemia.

Authors:  Ajay Gupta; Tulika Seth; Anuradha Gupta
Journal:  Pediatr Hematol Oncol       Date:  2009-01       Impact factor: 1.969

Review 7.  Medical and surgical management of priapism.

Authors:  J Cherian; A R Rao; A Thwaini; F Kapasi; I S Shergill; R Samman
Journal:  Postgrad Med J       Date:  2006-02       Impact factor: 2.401

8.  Malignant priapism due to penile metastases: Case series and literature review.

Authors:  Francesco De Luca; Evangelos Zacharakis; Majed Shabbir; Angela Maurizi; Emy Manzi; Antonio Zanghì; Carlo De Dominicis; David Ralph
Journal:  Arch Ital Urol Androl       Date:  2016-07-04

9.  [Priapism in pediatrics: initial presentation of chronic myeloid leukemia].

Authors:  Nadia Paladino; Daniela Roldán; María Soledad Caram
Journal:  Arch Argent Pediatr       Date:  2011-10       Impact factor: 0.694

10.  Priapism - A Rare Presentation in Chronic Myeloid Leukemia: Case Report.

Authors:  Rajendra B Nerli; Prasad V Magdum; Siddayya C Hiremath; Amey Y Patil; Suvarna V Pai; Rajeshwari S Handigund; M B Hiremath
Journal:  Urol Case Rep       Date:  2015-11-30
View more
  2 in total

1.  Priapism in patients with hemolytic disorders: a nationwide retrospective cohort study.

Authors:  Stinne Tranekær; Dennis Lund Hansen; Bart J Biemond; Anne Lykke Sørensen; Andreas Glenthøj; Jesper Petersen; Henrik Frederiksen
Journal:  Ann Hematol       Date:  2021-06-16       Impact factor: 3.673

2.  Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature.

Authors:  Shailendra Prasad Verma; Nidhish Kumar; Mili Jain; Anil K Tripathi
Journal:  Am J Case Rep       Date:  2020-07-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.